Booth: 601, 821, 606
AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
AcariaHealth is a national comprehensive specialty pharmacy focused on improving care and outcomes for patients living with complex and chronic health conditions, including Hepatitis C and other liver diseases. Our specialized care management services put patients first, bringing a personal touch to specialty drug management.
Accredo is a specialty pharmacy that serves patients with complex and chronic health conditions. Our specialty-trained pharmacists and nurses are available to provide personalized care to patients. Through Accredo’s 14 condition-specific Therapeutic Resource Centers (TRC) we deliver a level of expertise and care that is unmatched.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases, including lysosomal acid lipase deficiency (LAL-D), through the innovation, development and commercialization of life-changing therapies.
Alfa Wassermann clinical chemistry systems use liquid, ready-to-use reagents, providing an inexpensive alternative to dry chemistry. Alfa Wassermann offers a compact, cost-effective, easy-to-use, innovative benchtop blood chemistry analyzer to maximize research success by quickly and cost effectively transforming in-vivo drug safety and efficacy screens.
Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan’s website at www.Allergan.com.
Alnylam is leading the translation of RNA interference into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and CNS/ocular diseases. ONPATTRO® (patisiran) is Alnylam’s first U.S. FDA-approved RNAi therapeutic, with six investigational medicines in late-stage development. www.alnylam.com.
The Alpha-1 Foundation is a not-for-profit organization that is dedicated to providing the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency.
The American Board of Internal Medicine (ABIM) has stood for the highest standard in internal medicine and its 20 subspecialties. Certification has meant that internists have demonstrated – to their peers and to the public – that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care. ABIM is not a membership society, but a physician-led non-profit, independent evaluation organization.
Founded in 1976, the American Liver Foundation (ALF) is the nation’s leading nonprofit health organization for people living with liver disease. We are a nationwide network of staff and volunteers that provides awareness, outreach, education and patient support services to educate the public about liver health and to improve the lives of individuals and their families affected by liver disease.
The mission of the American Porphyria Foundation is to enhance awareness and education about the Porphyrias and to aid in advancing treatment of this group of disorders.
Amsety has developed the first nutrition bar to support liver health. Designed by a team of liver health specialists, scientists and food engineers, Amsety Bars meet the dietary requirements for liver diet. Amsety possesses a marketing database of around 300,000 qualified addresses of liver patients.
Today APASL is one of the leading associations based on investigation and treatment of liver diseases in the world and the largest scientific body that upholds the standards and profession, research and create improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region.
ALEH is a Non-profit scientific association, whose main objective is to promote and disseminate the study of Hepatology in Latin America. ALEH seeks to establish solid leadership within the field at a global level via diverse activities: Training and the exchange of scientific knowledge to reduce gaps in the region.
The Mexican Hepatology Association is a leading organization involved in the advancement of science and practice of hepatology, promoting better care for patients with liver and biliary diseases. It is involved in the innovation and development of new therapeutic options and is committed to the training of specialists.
The Autoimmune Hepatitis Association (AIHA) is a nonprofit that offers education and support for patients and families affected by autoimmune hepatitis. The AIHA hosts a biennial patient conference (next one is July 2019 in Indianapolis) and a social media community that connects patients with one another and with research opportunities.
Banner University Medical Center invites you to join our growing GI/Hepatology team (ACGME Accredited) on the campus of the University of Arizona in weather-perfect Tucson! Be part of a nationally-recognized health care system with a quality outcomes, patient-centered care and academic excellence. Faculty appointment with UofA consistent with your credentials.
Baxter products help make care options more accessible for critically-ill patients. We're advancing care for patients with drug overdose and poisoning, which can result in liver cell injury or death, and acute kidney injury worldwide. We provide a full range of dialysis, and drug overdose and poisoning therapy options, including MARS therapy and CRRT.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.
BioMatrix Specialty Pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health solutions for chronic, difficult to treat conditions. Our commitment provides individualized pharmacy services, timely access to care, focused education and support. We offer a tailored approach improving health and empowering patients to experience a higher quality of life.
BioPredictive is benchmark in blood tests for liver diseases. BioPredictive is dedicated to improve the management of liver diseases. Over 2.5 million tests performed worldwide. BioPredictive’s diagnosis and prognosis patented tests (FiboTest-ActiTest, SteatoTest, and just released in 2019 the NASH-Fibro Test) are available at www.biopredictive.com
Blue Faery: The Adrienne Wilson Liver Cancer Association is devoted to fighting primary liver cancer. Founded in Burbank, California, with a satellite location in Birmingham, Alabama, Blue Faery’s mission is to prevent, treat and cure primary liver cancer through research, education and advocacy. For more information, visit www.bluefaery.org.
Bon Secours Mercy Health is one of the top 20 health systems in the United States. With more than 57,000 employees, including over 2,300 employed physicians and APCs, we serve communities throughout Florida, Kentucky, Maryland, New York, Ohio, South Carolina and Virginia. For more information about our opportunities, visit mercy.com/physicianrecruitment.
BriovaRx is a leading specialty pharmacy services company dedicated to helping administer and deliver high-quality, cost-effective specialty pharmacy care. BriovaRx combines technology, data and expertise to provide educational resources, 24/7 pharmacy support and trusted advice to the individuals, caregivers and care teams we serve.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Visit BMS at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.
The Canadian Association for the Study of the Liver (CASL) is a multidisciplinary group of scientists and healthcare providers whose expertise focuses on the liver. We provide national leadership in all aspects of hepatology research, education and patient care, and publish the Canadian Liver Journal.
Discovery from Charles River is the CRO of choice with a proven track record of successful drug development. Offering scientific excellence and integrated services that take clients from hit ID to IND, our client-focused collaborative team works with clients to find and follow the optimum path to market.
Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer.
The Chronic Liver Disease Foundation (CLDF) is an educational organization dedicated to increasing the awareness of the effects of chronic liver disease in the United States. The CLDF's goal is to provide healthcare professionals with the most current education and information on chronic liver disease.
CN Bio Innovations develop human organ-on-chip technologies which enable the formation of miniature models of human organs in the lab. Our platform recreates the physiological and mechanical micro-environment of organs as well as permitting long-term culture of primary human cells, iPSC and cell lines. We provide products and services to both the biotechnology and Pharmaceutical industry.
The Cochrane Hepato-Biliary Group (CHBG), part of Cochrane, is a non-profit, non-industry funded international clinical research group with 2300 members. In issue 6, 2019 of The Cochrane Library, we published 371 peer-reviewed protocols and 223 systematic reviews. A CHBG Register with RCTs and CCTs is maintained in The Cochrane Library.
The Community Liver Alliance connects patients to health care providers and services; creates and conducts screenings and educational programs; supports local youth transplant camp; promotes awareness of liver wellness; offers a patient assistance program, funds local research and meets with local, state, and federal policy makers to initiate positive change.
CTI is a global, privately held, full-service CRO with a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. We specialize in the unique challenges associated with hepatic populations, and our therapeutic expertise is a driving force enabling us to successfully design/manage drug development programs in hepatology.
Our commitment to helping patients and their physicians manage complex drug therapies by delivering expert individualized care and unmatched, multi-channel access has made us one of the leading specialty pharmacies in the country. We provide a full-range of pharmaceutical care, dispensing the latest FDA-approved medications.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Diapharma offers non-invasive biomarker assays for research of liver injury, metabolic syndrome, and associated pathologies. Explore M30® and M65® Cytokeratin/Keratin 18 ELISAs for studying hepatocyte apoptosis/necrosis, and see what’s new in biomarkers for NASH, AH, and DILI research at booth 1224. Research use only in U.S. and Canada.
Founded on innovation and committed to consumer education, Diem Direct delivers clinically validated nutritional products that address underserved and unmet medical needs. Hepaxa® is a first-in-class medical food product consisting of a patented, concentrated and purified EPA/DHA complex, indicated for the management of steatosis in non-alcoholic fatty liver disease (NAFLD).
DILIsym Services, Inc. is committed to providing the pharmaceutical industry with the tools, resources and information to more efficiently develop safe and effective therapies for patients who need them. DILIsym Services, Inc. has developed and applies the DILIsym®, RENAsym™, and NAFLDsym® modeling software to support these objectives.
Hepatitis B vaccine is the only two-dose hepatitis vaccine for adults that completes the series in 1 month. It is the first approved hepatitis B vaccine in over 25 years and received a unanimous recommendation from the Advisory Committee on Immunization Practice.
Echosens™ is the world's leading provider of non-invasive, point of care medical devices for the liver. FibroScan ® is FDA cleared as an aid for the non-invasive diagnosis and monitoring of liver disease. Supported by over 2,000 peer reviewed publications Fibroscan is the reference for major treatment guidelines in liver disease.
Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of commercial focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Enanta Pharmaceuticals is focused on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets: respiratory syncytial virus , non-alcoholic steatohepatitis NASH/ primary biliary cholangitis, and hepatitis B virus.
ENDRA Life Sciences (NASDAQ: NDRA) is a development stage company with a breakthrough Thermo-Acoustic Enhanced UltraSound (TAEUS) device that will enable clinicians to visualize human tissue composition, function and temperature. Initial application is quantification of fat in the liver, for early detection and monitoring of NAFLD, which affects over 1 billion people globally.
Since 1966, EASL has continued to grow into a major European Association with international influence dedicated to liver research. It has over 4,500 members and its International Liver Congress™ unites over 9,000 liver experts. EASL supports clinical trials and research to the benefit of patients world-wide.
ExeGi Pharma distributes Visbiome, a high potency probiotic medical food intended for the dietary management of dysbiosis associated with irritable bowel syndrome, ulcerative colitis, pouchitis and hepatic encephalopathy. Visbiome offers a very high potency of bacteria ranging from 112.5 billion bacteria per CFU-900 billion bacteria per CFU, depending on the product. Visbiome is available in capsules, packets, and prescription-strength packets.
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Exelixis is on a mission to help patients recover stronger and live longer.
Fibronostics: A healthcare technology company dedicated to improving treatment screening, disease progression, and prognosis of chronic disease states and metabolic disorders with non-invasive, algorithmic technology.
FUJIFILM Wako Diagnostics offers biomarkers AFP-L3 (lectin-reactive alpha-fetoprotein) and DCP (des-gamma-carboxy prothrombin, also-known-as PIVKA-II), intended to aid in risk assessment of chronic liver disease patients for development of HCC in conjunction with other laboratory findings, imaging studies and clinical assessment. They are CMS reimbursed and available at major reference laboratories.
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a novel, once-daily, oral therapy for treating liver diseases and cholesterol gallstones. Aramchol is first-in-class in Galmed proprietary family of synthetic fatty-acid/bile-acid conjugates. It is initially being developed for treating Non-Alcoholic Steato-hepatitis, in patients with obesity and insulin resistance.
Gastroenterology & Endoscopy News, a monthly newspaper, provides smart, objective and comprehensive clinical news reporting from international, national and regional gastroenterology meetings. It also features in-depth original articles, educational reviews, CME monographs and monthly commentary from celebrated gastroenterologists.
Gastroenterology & Hepatology is a monthly, independent peer-reviewed journal that is mailed to all US gastroenterologists and hepatologists (16,700+). Content is directed by strong input of experts in the field. G&H contains thoughtful leader-driven review articles, clinical case studies with expert commentary, and advances columns featuring engaging interviews with experts on current issues in IBD, IBS, GERD, Hepatitis and Endoscopy.
Booth: 209, 114
GENFIT, a biopharmaceutical company focused on discovering and developing therapeutic and diagnostic solutions in metabolic/liver diseases, is evaluating elafibranor in a P3 trial in NASH as well as in PBC. GENFIT is also developing NIS4™, a novel blood-based in vitro diagnostic test to easily identify NASH patients.
Booth: 801, 1013, 1005, 813
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
GSK Oncology is dedicated to pursuing innovation in cancer care to make a difference for patients, physicians and communities. At GSK Oncology, what defines us is our pledge to engage and work with our communities as we strive to bring forth meaningful treatment choices.
The Global Liver Institute is a 501(c)(3) tax-exempt not-for-profit organization, headquartered in Washington, D.C. GLI’s vision is for liver health to take its place on the global public health agenda commensurate with its prevalence and impact. GLI’s mission is to improve the impact of the liver community by promoting innovation, collaboration, and scaling optimal approaches to eradicating liver diseases.
Gore Medical Products Division engineers devices that treat a range of cardiovascular, bariatric, hernia and other health conditions. Gore builds on its legacy of improving patient outcomes through research, education, and quality initiatives. Product performance, ease of use, and quality of service provide sustainable clinical and economic value for physicians, hospitals, and insurers.
We’re reporting LIVE. Follow what’s trending at Healio.com/GI. See what your peers are reading online – in print. Stop by our booth and pick up your free issue of Healio Gastroenterology and Liver Disease – a unique peer-tested news magazine. Go to Healio.com/Register.
The HealthWell Foundation is an independent non-profit dedicated to reducing financial barriers to care for underinsured Americans with chronic and life-altering medical conditions. HealthWell offers a financial lifeline to adults and children who desperately need critical medical treatments but can't afford them by assisting with their cost-sharing obligations. Learn more: www.HealthWellFoundation.org
Hep C Action Aotearoa brings patient voices to national and global elimination strategies of hepatitis C. The use of the hepatitis C butterfly is proving to be a key tool in elimination campaigns to confront the stigma surrounding the virus.
HEPATIQ is the first automated nuclear medicine software to precisely quantitate liver function. Elastography estimates liver fibrosis (scarring) and does not measure liver function. Estimating fibrosis is not enough as the liver regenerates and perfusion increases to compensate for fibrosis. It is the residual liver function that determines disease outcomes.
Life science product and service consulting company focused on assisting our med-tech, pharmaceutical, and bioscience clients with strategic and operational growth plans. We help our clients identify and communicate their products and services’ clinical and economic outcomes.
IIAM is a world-leading provider of non-transplantable, human organs and tissues for medical research, therapeutic applications and pre-clinical investigations. As a non-profit with more than 30 years of experience in the field, IIAM is a known and trusted partner to both organ procurement organizations and research institutions worldwide. www.iiam.org.
Indiana University Health is known for state-of-the-art medical services and patient care. That legacy means furthering the development of clinical and academic advancements in liver conditions, including comprehensive transplant care for life, from experienced and innovative physicians and an entire care team committed to ensuring better transplant outcomes.
INDIGO Biosciences, Inc. has established itself as the industry-leading provider of assay kits and screening services focused on nuclear receptors. With the world’s largest portfolio, INDIGO products and services help customers improve the speed to data, accuracy, ease of use, and cost efficiency of their drug discovery research.
InSphero is the pioneer of scalable, 3D-cell-based assay solutions and organ-on-a-chip technology for drug discovery and safety testing. Through partnerships, InSphero supports pharma and biotech researchers in successful decision-making with innovative 3D in vitro platforms and models that accurately recapitulate healthy and diseased human physiology.
Booth: 317, 921
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
KCI Biotech (SUZHOU) Inc. (KCI) is a preclinical Contract Research Organization (CRO) providing specialty preclinical pharmacology services in cardiovascular diseases, immune diseases, inflammatory diseases, metabolic diseases, urinary diseases, neuron diseases and oncology by using small and large animal disease models.
Covance is the world's most comprehensive drug development company. LabCorp, our parent company, is a market leader in diagnostics with strength in the management of infectious diseases. Together, we offer a single-source solution for drug development and treatment of acute and chronic infections. Together, we improve health and improve lives.
Laboratory for Advanced Medicine (LAM), is a commercial-stage medical technology company focused on developing noninvasive, nontoxic technologies for the early diagnosis and intervention of cancers. The IvyGene Dx Liver Cancer Test is a highly sensitive and specific blood test that has the potential to detect the presence of liver cancer, as early as Stage I.
Madrigal Pharmaceuticals is a biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver to address a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Resmetirom, the lead compound, is currently being evaluated in the global Phase 3 study MAESTRO-NASH.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. To learn more visit www.mallinckrodt.com
Are you monitoring the progression of NASH patients using noninvasive serum tests? Is your HCV drug resistance testing process simplified to quickly arrive at clinically actionable answers? From screening to therapeutic management, our full menu of GI testing makes it simple to order what you need, all in one place.
MYR Pharmaceuticals is focused on the development of bulevirtide, a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. MYR started its operations in 2011. Its technology was originally developed at the University of Heidelberg, INSERM and now represents one the most clinically advanced novel approaches for treatment of hepatitis B/D.
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) exhibit highlights the importance of alcohol research, prevention, and treatment for maintaining health. The NIAAA booth features publications appropriate for the public, research findings for professionals and policy makers, and research grant opportunities available for biomedical and social science researchers.
NOhep, the global movement to eliminate viral hepatitis bought to you by the World Hepatitis Alliance, invites medical professionals to become NOhep Medical Visionaries. Visit the NOhep stand to join an international network of leading healthcare professionals sharing best practice examples of service improvement, patient engagement and micro-elimination.
Novartis, a leading global medicines company, is reimagining medicine to improve and extend people’s lives through innovation and digital technologies to create transformative treatments in areas of great medical need. Novartis reaches more than 750 million people and we are finding innovative ways to expand access to our latest treatments.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders, obesity, chronic kidney disease, cardiovascular disease and NASH.
OraSure Technologies manufactures oral fluid devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for HIV and HCV antibodies, influenza antigens, testing solutions for detecting drugs of abuse, and oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.
PBCers Organization is a nonprofit offering support and education to patients with Primary Biliary Cholangitis with our online resources and hosting a biennial patient conference. We raise funds for research, connect patients with research opportunities and our patient registry assists future research.
Perspectum Diagnostics provides digital health solutions for metabolic disease. LiverMultiScan, uses multiparametric MRI to provide quantitative analysis of liver tissue, measuring fat, correlates of iron and fibroinflammatory disease. MRCP+, allows 3D visualisation and quantitative mapping of the pancreatobiliary system by enhancing conventional MRCP images
PhoenixBio provides access to the PXB-Mouse® (chimeric mouse model featuring a humanized liver, up to 98% human hepatocyte engraftment) and PXB-cells® (human hepatocytes freshly isolated from PXB-mice) for in vivo and in vitro liver related research areas. PhoenixBio models accelerate pharmaceutical and chemical compound development by better predicting human outcomes.
Precision MedCare is a Medical AI startup founded in Atlanta. Based on its proprietary technology that utilizes ultrasound Doppler device to measure, Precision MedCare offers hospitals and clinics new and accurate solutions for liver fibrosis detection.
Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties.
ProSciento is a specialty CRO exclusively focused on NASH, diabetes and obesity. ProSciento provides comprehensive and customized services for multinational, early development clinical trial programs for biopharma companies worldwide. Founded in 2003, ProSciento has completed over 280 clinical projects and contributed to more than 15 approved metabolic drugs and devices.
Founded within Providence St. Joseph Health, Provider Solutions + Development is a purpose-filled clinical career navigation organization. For 20+ years, we’ve helped thousands of physicians and providers achieve their practice potential. Our growing network of health system partners offers innovative care models, diverse practice locations across the nation, and a shared culture of service.
PSC Partners Seeking a Cure provides education and support to PSC patients, families and caregivers, and raises funds to research causes, treatments and cures for Primary Sclerosing Cholangitis. PSC Partners has awarded $3 million in research grants, has a growing patient registry, and holds annual conferences for patients and caregivers.
Recordati Rare Diseases is a biopharmaceutical company committed to providing often overlooked orphan therapies to the underserved rare disease communities of the United States. Our experienced team works side-by-side with rare disease communities to increase awareness, improve diagnosis, and expand availability of treatments. For more information, please visit www.recordatirarediseases.com/us.
Research Diets, Inc. formulates and produces purified OpenSource Diets® for laboratory animals. Custom diets shipped in 5-7 days. BioDAQ® Food and Liquid Intake Monitor for mice and rats mounts to home cage and records the time, duration, amount of each meal automatically. BioDAQ NHP monitors food intake of socially housed NHPs.
Resoundant Inc. is the developer of Magnetic Resonance Elastography (MRE), an advanced imaging technology for measuring tissue stiffness and aiding the diagnosis and staging of liver fibrosis. MRE is available at over 1300 leading imaging centers and hospitals throughout the world. Follow us @Resoundant or visit us at Booth # 627.
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease.
For 30 years, Salix Pharmaceuticals has been committed to the prevention and treatment of gastrointestinal diseases. Salix licenses, develops and markets innovative products to improve patients’ lives and arm healthcare providers with life-changing solutions. Salix is headquartered in Bridgewater, New Jersey.
Sanyal Biotechnology is a full-service contract research organization specializing in pre-clinical small animal model screening of drugs. Our flagship DIAMOND™ mouse develops full metabolic syndrome solely as a result of Western Diet. We have the capability to screen drugs throughout the development timeline from basic toxicology to efficacy.
Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a drug discovery-based pharmaceutical company founded in Osaka, Japan 139 years ago. Our focus is on developing the best possible medicines that address unmet medical needs and help patients and their families worldwide.
Siemens Healthcare help you address challenging clinical needs in the management of patients with chronic liver disease and the assessment of liver fibrosis, including Virtual Touch™ software applications* on the ACUSON S2000 ultrasound system, (an implementation of acoustic radiation force impulse (ARFI) imaging).
TASLF was founded in January 1990, which enhance the medical education and academic intercommunication for hepatology, and reinforce the interconnection with other international hepatology groups. TASLF is also the organizer of Global Hepatitis Summit (ISVHLD GHS 2020). The event will take place on June 18-21, 2020 in Taipei, Taiwan.
Since the program's inception in 1981, UPMC Transplant Services has been a pioneer in the development and refinement of new transplant procedures. UPMC is committed to reducing waiting list deaths through robust living-donor kidney and living-donor liver transplant programs, as well as other innovative methods to expand the donor pool.
Virology Education is a leading provider of innovative scientific and educational programs worldwide, with over 20 years of experience and a wide network of experts. Our programs provide platforms for scientific exchange, education and knowledge-sharing tailored to the needs of healthcare professionals in the fields of virology and liver disease.
Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects.
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments, and individuals increase the academic and professional impact of their work.
Woodland Biosciences is a preclinical CRO focused on metabolic liver diseases including fatty liver disease (NAFLD), NASH and HCC. We have a rich and varied model capabilities for liver pathologies including obesity, hyperglycemia, inflammation and fibrosis. Our cancer expertise is focused on liver, pancreatic, colon and glioblastoma.
The World Gastroenterology Organisation (WGO) is a federation comprised of over 110 gastroenterology, hepatology, endoscopy, and other related-discipline societies representing more than 50,000 individuals worldwide. WGO focuses on the improvement of standards in gastroenterology training and education globally. The WGO Foundation is the philanthropic resource for the WGO mission.
WuXi AppTec is a global pharmaceutical and medical device open-access capability and technology platform company. As an innovation-driven and customer-focused organisation, WuXi AppTec provides a broad and integrated portfolio of services to help our partners shorten the discovery and development time through cost-effective and efficient solutions. Please visit www.wuxiapptec.com.
Liver-Humanized FRG®KO mice provide researchers with actionable insights into liver-specific questions at the cellular, tissue, and animal level. For more than a decade, scientists have used the FRG®KO platform as a tool for NASH, gene therapy, infectious diseases, and DMPK applications to achieve human relevance in their research.